(MYGN) Myriad Genetics - Performance -83.2% in 12m
Compare MYGN with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-66.38%
#75 in Group
Rel. Strength
7.72%
#7343 in Universe
Total Return 12m
-83.17%
#128 in Group
Total Return 5y
-74.69%
#64 in Group
P/E -
(?) Percentile in Group
P/E Forward 97.1
90th Percentile in Group
PEG 1.40
88th Percentile in Group
FCF Yield -5.93%
78th Percentile in Group
12m Total Return: MYGN (-83.2%) vs XBI (-12.3%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
10.1% | 18% | 166% | 12.1 | 11 | 1.43 | 74.6% | 16.1% |
HLN NYSE Haleon |
14.3% | 31.2% | 47% | 24.4 | 20.2 | 1.79 | 69.1% | 13.6% |
AMGN NASDAQ Amgen |
-2.93% | -8.78% | 30.7% | 25.5 | 13.5 | 0.95 | 0.60% | 41% |
LONN SW Lonza |
9.55% | 9.34% | 30.4% | 67.1 | 35.1 | 1.28 | 2.20% | -12.5% |
BIM PA Biomerieux |
0.78% | 17.8% | -2.14% | 32.5 | 25.2 | 1.52 | -38.5% | -25.1% |
KMDA NASDAQ Kamada |
21.4% | 25.3% | -4.13% | 26.6 | 23.9 | 0.96 | 32.5% | 3.93% |
NBIX NASDAQ Neurocrine Biosciences |
34.3% | -15.5% | 3.48% | 32.3 | 21.6 | 0.27 | 68.0% | 31.9% |
ERF PA Eurofins Scientific SE |
20.4% | -0.39% | 7.63% | 26.6 | 13.6 | 0.56 | -66.6% | -17.1% |
Performance Comparison: MYGN vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for MYGN
Total Return (including Dividends) | MYGN | XBI | S&P 500 |
---|---|---|---|
1 Month | -47.87% | 11.81% | 13.81% |
3 Months | -67.63% | -13.61% | -6.30% |
12 Months | -83.17% | -12.29% | 10.65% |
5 Years | -74.69% | -24.89% | 107.77% |
Trend Score (consistency of price movement) | MYGN | XBI | S&P 500 |
1 Month | -78.1% | 72.9% | 83% |
3 Months | -97.4% | -83% | -75.3% |
12 Months | -85.2% | -51.6% | 50.1% |
5 Years | -20.0% | -53.9% | 84.1% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #180 | -53.4% | -54.2% |
3 Month | #170 | -62.5% | -65.5% |
12 Month | #128 | -80.8% | -84.8% |
5 Years | #63 | -66.3% | -87.8% |
FAQs
Does MYGN Myriad Genetics outperforms the market?
No,
over the last 12 months MYGN made -83.17%, while its related Sector, the SPDR S&P Biotech (XBI) made -12.29%.
Over the last 3 months MYGN made -67.63%, while XBI made -13.61%.
Over the last 3 months MYGN made -67.63%, while XBI made -13.61%.
Performance Comparison MYGN vs Indeces and Sectors
MYGN vs. Indices MYGN is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | -44.7% | -61.7% | -71.9% | -93.8% |
US NASDAQ 100 | QQQ | -44.9% | -65.2% | -72.1% | -94.8% |
US Dow Jones Industrial 30 | DIA | -45.1% | -57.9% | -71.6% | -90.9% |
German DAX 40 | DAX | -44.6% | -62.8% | -98.2% | -109% |
Shanghai Shenzhen CSI 300 | CSI 300 | -46.8% | -59.7% | -72.7% | -90.5% |
Hongkong Hang Seng | HSI | -47.8% | -67.8% | -80.3% | -96.9% |
India NIFTY 50 | INDA | -39.7% | -52.7% | -72.4% | -83.0% |
Brasil Bovespa | EWZ | -45.7% | -65.1% | -80.6% | -74.8% |
MYGN vs. Sectors MYGN is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | -45.3% | -61.3% | -79.0% | -105% |
Consumer Discretionary | XLY | -45.0% | -62.1% | -70.9% | -97.4% |
Consumer Staples | XLP | -43.8% | -54.5% | -78.8% | -92.3% |
Energy | XLE | -44.5% | -54.6% | -65.3% | -73.7% |
Financial | XLF | -45.8% | -61.4% | -79.0% | -106% |
Health Care | XLV | -41.7% | -48.7% | -66.9% | -79.1% |
Industrial | XLI | -46.4% | -64.7% | -73.3% | -94.2% |
Materials | XLB | -44.5% | -61.4% | -67.0% | -77.9% |
Real Estate | XLRE | -43.3% | -59.4% | -72.7% | -98.6% |
Technology | XLK | -45.7% | -69.1% | -69.0% | -90.3% |
Utilities | XLU | -44.7% | -57.5% | -79.6% | -101% |
Aerospace & Defense | XAR | -46.6% | -69.0% | -83.4% | -111% |
Biotech | XBI | -38.1% | -59.7% | -51.8% | -70.9% |
Homebuilder | XHB | -45.1% | -59.4% | -58.7% | -75.6% |
Retail | XRT | -46.6% | -62.5% | -67.7% | -81.7% |